A THREE ARM, multi-centre,
randomised, double-blind,
active-controlled study comparing
alogliptin (Nesina) plus metformin
with glipizide plus metformin over a
two year period has demonstrated
its primary endpoint.
Royal Prince Alfred Hospital
Head of the Endocrinology Dept
and Endocrinology Research
Laboratories, Professor Stephen
Twigg said the results provided
a “compelling basis to consider
alogliptin’s use early in the
treatment pathway.”The above article was sent to subscribers in Pharmacy Daily's issue from 26 Aug 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 Aug 14
MEDICATION management platform MedAdvisor Limited (MDR) showed strong financial performance for the quarter concluded on 31 Mar 2024, with operating revenue up 42% to $24.2 million from $17 million for the same period last year.
PHARMACIES in regional areas need a restructure of the 8CPA Community Service Obligation (CSO) to help fund them to support their workforce and deliver services, says the Remote and Isolated Pharmacist Association Australia (RIPAA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.